Wake Forest University School of Medicine is the medical school of Wake Forest University, with two campuses located in Winston-Salem, North Carolina and Charlotte, North Carolina, United States.

During the past decade, Wake Forest University School of Medicine conducted 115 clinical trials. In the 10-year time frame, 115 clinical trials started and 67 clinical trials were completed, i.e. on average, 58.3% percent of trials that started reached the finish line to date. In the past 5 years, 51 clinical trials started and 39 clinical trials were completed. i.e. 76.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wake Forest University School of Medicine" #1 sponsor was "Wake Forest University Health Sciences" with 48 trials, followed by "Boston Scientific Corporation" with 12 trials sponsored, "Abbott Medical Devices" with 8 trials sponsored, "The George Washington University Biostatistics Center" with 7 trials sponsored and "Wake Forest University" with 7 trials sponsored. Other sponsors include 165 different institutions and companies that sponsored additional 130 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wake Forest University School of Medicine" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 10 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 10 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 7 trials as a collaborator, "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 7 trials as a collaborator and "National Institute on Aging (NIA)" with 6 trials as a collaborator. Other collaborators include 105 different institutions and companies that were collaborators in the rest 97 trials.

According to Clinical.Site data, the most researched conditions in "Wake Forest University School of Medicine" are "HIV Infections" (13 trials), "Coronary Artery Disease" (6 trials), "Amyotrophic Lateral Sclerosis" (5 trials), "Breast Cancer" (5 trials) and "Obesity" (5 trials). Many other conditions were trialed in "Wake Forest University School of Medicine" in a lesser frequency.

Most popular intervention types in "Wake Forest University School of Medicine" are "Drug" (133 trials), "Device" (46 trials), "Other" (28 trials), "Behavioral" (21 trials) and "Biological" (15 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "placebo" (7 trials), "Zidovudine" (4 trials), "lenalidomide" (4 trials) and "Didanosine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Wake Forest University School of Medicine" are 225 trials for "All" genders, 20 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 49 active trials in "Wake Forest University School of Medicine". 4 are not yet recruiting, 24 are recruiting, 20 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 160 completed trials in Wake Forest University School of Medicine, 1 suspended trials, and 28 terminated clinical trials to date.

Out of the total trials that were conducted in Wake Forest University School of Medicine, 10 "Phase 1" clinical trials were conducted, 60 "Phase 2" clinical trials and 79 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 68 trials that are defined as “Not Applicable".